Stemline Therapeutics Inc (STML)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

750 LEXINGTON AVENUE NEW YORK, NY 10022

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas.

Data as of 2020-06-06
Market Cap625.929 Million Shares Outstanding52.511 Million Avg 30-day Volume2.499 Million
P/E Ratio Dividend Yield EPS-1.58
Price/Sales13.306 Price cash flow ratio Price free cash flow ratio-10.5
Book Value2.81 Price to Tangible Book4.24 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.101147
BETA1.70611 52-week High/Low18.22 / 3.21 Stddev0.230285
View SEC Filings from STML instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 2 (0.13%)
13F Filers holding this stock: 94 29 (1.9%)
Aggregate 13F shares on 03/31/2020: 39.652 Million 19.617 Million
Aggregate 13F shares on 12/31/2019: 41.233 Million 20.192 Million
Percent change: -3.84% -2.84%
Funds creating new positions: 17 6
Funds Adding to an existing position: 34 9
Funds closing out their position: 20 11
Funds reducing their position: 26 11
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding STML (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding STML BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

272 total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HOBERMAN KENNETH

  • Director
158,953 2020-06-22 7

HUME DANIEL

  • Director
134,507 2020-06-22 1

DOBMEIER ERIC

  • Director
28,000 2020-06-16 0

ROWINSKY ERIC K

  • Director
0 2020-06-16 0

BUCHI J KEVIN

  • Director
0 2020-06-15 0

BENTSUR RON

  • Director
0 2020-06-10 1

ZUERBLIS KENNETH J

  • Director
0 2020-06-10 1

BERGSTEIN IVAN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-06-10 7

GIONCO DAVID CHIEF ACCOUNTING OFFICER

  • Officer
0 2020-06-10 8

FORMAN ALAN S

  • Director
0 2020-06-10 3

SARD MARK

  • Director
0 2020-06-10 1

CLINE DARREN S

  • Director
0 2020-06-10 1

FRANCOMANO ROBERT CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-06-10 6

BERGSTEIN IVAN CHIEF EXECUTIVE OFFICER

BERGSTEIN IVAN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
2,726,151 2019-02-25 7

HALL STEPHEN P EVP & CHIEF FINANCIAL OFFICER

  • Officer
31,034 2016-03-31 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

FRANCOMANO ROBERT - Officer CHIEF COMMERCIAL OFFICER

2020-06-10 U 200,891 d 0 0.00 direct

HOBERMAN KENNETH - Officer CHIEF OPERATING OFFICER

2020-06-10 U 1,374,352 d 0 0.00 direct

BENTSUR RON - Director

2020-06-10 D 34,000 d 0 0.00 direct

BENTSUR RON - Director

2020-06-10 U 66,346 d 0 0.00 direct

BERGSTEIN IVAN - Director - Officer CHIEF EXECUTIVE OFFICER

2020-06-10 D 90,352 d 0 0.00 direct

HUME DANIEL - Director

2020-06-10 U 35,468 d 0 0.00 direct

GIONCO DAVID - Officer CHIEF ACCOUNTING OFFICER

2020-06-10 U 327,878 d 0 0.00 direct

ZUERBLIS KENNETH J - Director

2020-06-10 D 34,000 d 0 0.00 direct

FORMAN ALAN S - Director

2020-06-10 D 34,000 d 0 0.00 direct

CLINE DARREN S - Director

2020-06-10 U 35,468 d 0 0.00 direct

HOBERMAN KENNETH - Officer CHIEF OPERATING OFFICER

2020-06-10 D 44,058 d 0 0.00 direct

HOBERMAN KENNETH - Officer CHIEF OPERATING OFFICER

2020-06-10 A 600,000 a 1,374,352 0.00 direct

BENTSUR RON - Director

2020-06-10 D 18,070 d 0 0.00 direct

BERGSTEIN IVAN - Director - Officer CHIEF EXECUTIVE OFFICER

2020-06-10 D 356,700 d 0 0.00 direct

BERGSTEIN IVAN - Director - Officer CHIEF EXECUTIVE OFFICER

2020-06-10 U 3,024,336 d 0 0.00 direct

SARD MARK - Director

2020-06-10 U 51,468 d 0 0.00 direct

GIONCO DAVID - Officer CHIEF ACCOUNTING OFFICER

2020-06-10 A 45,000 a 327,878 0.00 direct

ZUERBLIS KENNETH J - Director

2020-06-10 U 60,121 d 0 0.00 direct

FORMAN ALAN S - Director

2020-06-10 U 88,298 d 0 0.00 direct

FRANCOMANO ROBERT - Officer CHIEF COMMERCIAL OFFICER

2020-06-10 D 50,000 d 0 0.00 direct

HOBERMAN KENNETH - Officer CHIEF OPERATING OFFICER

2020-06-10 D 25,000 d 0 0.00 direct

BENTSUR RON - Director

2020-06-10 D 24,000 d 0 0.00 direct

BENTSUR RON - Director

2020-06-10 D 9,034 d 0 0.00 direct

BERGSTEIN IVAN - Director - Officer CHIEF EXECUTIVE OFFICER

2020-06-10 D 180,704 d 0 0.00 direct

BERGSTEIN IVAN - Director - Officer CHIEF EXECUTIVE OFFICER

2020-06-10 A 220,000 a 3,024,336 0.00 direct

GIONCO DAVID - Officer CHIEF ACCOUNTING OFFICER

2020-06-10 D 45,102 d 0 0.00 direct

ZUERBLIS KENNETH J - Director

2020-06-10 D 24,000 d 0 0.00 direct

FORMAN ALAN S - Director

2020-06-10 D 24,000 d 0 0.00 direct

FRANCOMANO ROBERT - Officer CHIEF COMMERCIAL OFFICER

2020-05-04 S 272 $11.51 d 197,658 197,658.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments